Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy

ABSTRACT: Interventions: Bevacizumab(10mg/kg) plus FOLFIRI Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2617884 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR